Merck announced results from two post-hoc analyses of the TRA 2°P TIMI 50 (Thrombin Receptor Antagonist in Secondary Prevention of Atherothrombotic Ischemic Events) trial of Zontivity (vorapaxar), one of the largest secondary prevention studies of an antiplatelet medicine.

Mountain States Health Alliance (MSHA) wanted consistency in care and data reporting from all its facilities, and through use of its CVIS it was able to greatly improve workflow, cut reporting time, reduce critical results turnaround times with chest pain patients in the emergency department, and improve quality data reporting standards.Ā 

TomTec Imaging Systems GmbH will introduce its 4-D RV-Function software for right ventricular function analysis at the 64th Annual Scientific Session of the American College of Cardiology (ACC. 2015).

A three-year review of data on the Combo Dual Therapy Stent was presented at the Joint Interventional Meeting (JIM) 2015 in Rome. These data demonstrate the healing benefits of the Combo Dual Therapy Stent in the treatment of coronary artery disease in the short, medium and long-term.


As an early adopter of fractional flow reserve (FFR) for the diagnosis of ischemia, my initial decision to transition from angiographic-guided treatment to physiologic-guided treatment was driven by a desire to ensure that we were treating lesions appropriately. Despite countless studies indicating the weakness of the angiogram, far too many operators still rely on it for treatment guidance. The coronary angiogram is limited and does not measure the extent to which a stenosis is restricting blood flow.


Biotronik announced that its ProMRI and ProMRI AFFIRM studies have been published inĀ Heart Rhythm,Ā the official journal of the Heart Rhythm Society, validating the safety testing of Biotronik’sĀ ProMRIĀ technology.

The Centers for Medicare and Medicaid Services (CMS) has released theĀ 2015 National Impact Assessment of Quality Measures ReportĀ (2015 Impact Report).

Subscribe Now